Abstract / Summary
Supporting materials for a systematic review and meta-analysis of randomised, placebo-controlled trials of semaglutide in adults with and without type 2 diabetes (PROSPERO CRD420261496524). Contents:(1) the standardised data extraction sheet used to record trial characteristics, risk-of-bias judgements and outcome data for the seven included trials;(2) the analysis code used to reproduce all pooled effect estimates — hazard ratios for MACE-3, the kidney composite endpoint, heart-failure hospitalisation/events, and all-cause and cardiovascular death, and the mean difference for the annual eGFR slope — together with heterogeneity statistics, prediction intervals, prespecified subgroup and sensitivity analyses, publication-bias tests and trial sequential analysis;(3) the complete search strategies and search records for PubMed/MEDLINE, Embase, CENTRAL, ClinicalTrials.gov and the WHO ICTRP, including the deduplicated record set;(4) the figure-generation code for all main and supplementary figures; and(5) the trial-by-trial exclusion-reason mapping for all 4,414 screened records, which underlies Appendix B of the manuscript: one row per record with its screening stream, final decision and exclusion category. The code also performs the analyses added during revision: restricted maximum likelihood estimation of tau-squared alongside the primary maximum likelihood estimates, a k = 4 eGFR-slope sensitivity analysis in which the two estimates taken from the same post hoc analysis enter as a single input, leave-one-out analysis of the kidney composite endpoint, and absolute effects (events avoided per 1000 participants and numbers needed to treat). Changes in this version: the README now cites the concept DOI 10.5281/zenodo.22840501, and the trial-by-trial exclusion-reason mapping (item 5) has been added. This version supersedes doi:10.5281/zenodo.22841839, which contains only the data extraction sheet and the README. No copyrighted full texts of the included publications are included, and no individual participant data were used: all analyses are based on published trial-level summary statistics.